AR078793A1 - Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros - Google Patents

Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros

Info

Publication number
AR078793A1
AR078793A1 ARP100103942A ARP100103942A AR078793A1 AR 078793 A1 AR078793 A1 AR 078793A1 AR P100103942 A ARP100103942 A AR P100103942A AR P100103942 A ARP100103942 A AR P100103942A AR 078793 A1 AR078793 A1 AR 078793A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
heterocyclic ring
alkylamino
hydroxyalkyl
Prior art date
Application number
ARP100103942A
Other languages
English (en)
Spanish (es)
Inventor
Pia Knuuttila
Olli Tormakangas
Harri Salo
Lisa Hoglund
Sirpa Rasku
Anniina Vesalainen
Arja Karjalainen
Gerd Wohlfahrt
Patrik Holm
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43383475&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR078793(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of AR078793A1 publication Critical patent/AR078793A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP100103942A 2009-10-27 2010-10-26 Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros AR078793A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25515909P 2009-10-27 2009-10-27

Publications (1)

Publication Number Publication Date
AR078793A1 true AR078793A1 (es) 2011-12-07

Family

ID=43383475

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103942A AR078793A1 (es) 2009-10-27 2010-10-26 Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros

Country Status (36)

Country Link
US (5) US8975254B2 (en.)
EP (5) EP3369732B1 (en.)
JP (1) JP5763083B2 (en.)
KR (2) KR101670299B1 (en.)
CN (2) CN105061313B (en.)
AR (1) AR078793A1 (en.)
AU (1) AU2010311299C1 (en.)
BR (1) BR112012008823B8 (en.)
CA (1) CA2777896C (en.)
CL (1) CL2012000772A1 (en.)
CO (1) CO6531494A2 (en.)
CY (2) CY2020010I1 (en.)
DK (3) DK2493858T3 (en.)
EA (1) EA021170B1 (en.)
ES (3) ES2877248T3 (en.)
GE (1) GEP20166472B (en.)
HK (1) HK1173442A1 (en.)
HR (3) HRP20140919T1 (en.)
HU (2) HUE055528T2 (en.)
IL (2) IL218586A (en.)
LT (3) LT3056485T (en.)
LU (1) LUC00154I2 (en.)
MX (1) MX2012004867A (en.)
MY (1) MY159924A (en.)
NL (1) NL301041I2 (en.)
NO (1) NO2020018I1 (en.)
NZ (1) NZ598747A (en.)
PE (1) PE20121058A1 (en.)
PL (3) PL2493858T3 (en.)
PT (3) PT3056485T (en.)
RS (3) RS53469B (en.)
SI (3) SI3369732T1 (en.)
SM (1) SMT201400138B (en.)
UA (1) UA109535C2 (en.)
WO (1) WO2011051540A1 (en.)
ZA (1) ZA201202655B (en.)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2603032T3 (es) * 2010-07-15 2017-02-23 Bayer Intellectual Property Gmbh Compuestos de 3-piridil-heteroarilcarboxamida como pesticidas
CN103492372B (zh) * 2011-04-21 2015-09-30 奥赖恩公司 调节雄激素受体的甲酰胺类化合物
EP2574607A1 (en) * 2011-09-06 2013-04-03 F. Hoffmann-La Roche AG PDE10 modulators
CA2867174C (en) * 2012-03-15 2020-06-23 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
CN104302644A (zh) * 2012-03-23 2015-01-21 日本农药株式会社 噻唑甲酰胺衍生物及其使用方法
SG11201408316SA (en) 2012-06-15 2015-03-30 Taisho Pharmaceutical Co Ltd Branched chain alkyl heteroaromatic ring derivative
WO2014031784A1 (en) 2012-08-23 2014-02-27 Alios Biopharma, Inc. Compounds for the treatment of paramoxyvirus viral infections
CN102952095A (zh) * 2012-10-19 2013-03-06 盛世泰科生物医药技术(苏州)有限公司 一种2-羧酸乙酯-5-溴甲基噻唑的合成方法
AU2014308991B2 (en) * 2013-08-21 2019-02-14 Janssen Biopharma, Inc. Antiviral compounds
WO2015172196A1 (en) * 2014-05-13 2015-11-19 Monash University Heterocyclic compounds and use of same
KR20200052995A (ko) 2015-01-20 2020-05-15 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
DK3250554T3 (da) * 2015-01-30 2022-06-27 Orion Corp Carboxamidderivat og diastereomerer deraf i stabil, krystallinsk form
MA41614A (fr) * 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
PE20171738A1 (es) 2015-04-09 2017-12-04 Orion Corp Proceso para la preparacion de antagonistas del receptor androgeno e intermediarios de los mismos
CA3024113A1 (en) * 2015-05-18 2016-11-24 Translational Drug Development, Llc Heterocyclic compounds as kinase inhibitors
CN107056755B (zh) * 2015-12-07 2019-02-22 苏州信诺维医药科技有限公司 五元杂环酰胺类wnt通路抑制剂
CN107286094A (zh) * 2016-04-12 2017-10-24 常州爱诺新睿医药技术有限公司 一种bay-1841788与药用辅料的固体分散体及其制备方法
DK3495352T3 (da) * 2016-08-26 2021-05-03 Crystal Pharmaceutical Suzhou Co Ltd Krystalformer af en androgenreceptorantagonist, fremgangsmåde til fremstilling og anvendelse deraf
DK3660004T3 (da) 2016-10-11 2023-05-08 Arvinas Operations Inc Forbindelser og fremgangsmåder til målrettet degradering af androgenreceptor
AU2018229817B2 (en) 2017-03-07 2021-09-30 Orion Corporation Manufacture of a crystalline pharmaceutical product
CA3068324A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
US11236073B2 (en) 2017-08-09 2022-02-01 Hangzhou Solipharma Co., Ltd. ODM-201 crystalline form, preparation method therefor, and pharmaceutical composition thereof
CN107602471B (zh) * 2017-09-22 2021-04-27 成都恒汇化成医药科技有限公司 一种达罗鲁胺的晶型制备方法
JP2021515040A (ja) * 2018-02-27 2021-06-17 サンド・アクチエンゲゼルシヤフト ダロルタミドの結晶形態ｉｉ
US20220062281A1 (en) * 2018-08-13 2022-03-03 National Centre For Biological Sciences-Tifr Inhibitors to target hiv-1 nef-cd80/cd86 interactions for therapeutic intervention
WO2020095183A1 (en) 2018-11-05 2020-05-14 Pfizer Inc. Combination for treating cancer
US20220160695A1 (en) 2019-01-30 2022-05-26 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
JP7241435B2 (ja) * 2019-02-27 2023-03-17 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピラゾール系化合物および該当化合物を含む組成物並びにその使用
CN114144168A (zh) 2019-07-02 2022-03-04 奥赖恩公司 达鲁酰胺的药物组合物
CN110590668A (zh) * 2019-07-17 2019-12-20 江苏君若医药有限公司 N-[(1s)-2-[3-(3-氯-4-氰基苯基)-1h-吡唑-1-基]-1-甲基乙基]-5-(1-羟基乙基)- 1h-吡唑-3-甲酰胺的制备方法
MX2022001450A (es) 2019-08-08 2022-04-20 Laekna Ltd Metodo de tratamiento del cancer.
CN111116476A (zh) * 2019-12-27 2020-05-08 武汉九州钰民医药科技有限公司 制备抗肿瘤药物多拉米胺的方法
CN115605470A (zh) 2020-05-11 2023-01-13 奥赖恩公司（Fi） 制备雄激素受体拮抗剂及其中间体的方法
KR20230057384A (ko) 2020-08-13 2023-04-28 화이자 인코포레이티드 조합 요법
CN111978534B (zh) * 2020-09-07 2022-05-31 陕西师范大学 一种含苯并咪唑液晶基元的侧链型液晶离聚物及其制备方法
BR112023018906A2 (pt) 2021-03-24 2023-10-10 Astellas Pharma Inc Combinação de talazoparib e um antiandrógeno para o tratamento de câncer de próstata metastático sensível à castração com mutação no gene ddr
CN113527208A (zh) * 2021-08-31 2021-10-22 江西金丰药业有限公司 一步法制备2-氯-4-（1h-吡唑-3-基）苯甲腈的方法
CN113861115A (zh) * 2021-09-10 2021-12-31 浙江师范大学 一种吡唑酰胺类衍生物及合成方法和应用
WO2023161458A1 (en) 2022-02-28 2023-08-31 Química Sintética, S.A. Crystalline form of darolutamide
WO2023194528A1 (en) 2022-04-07 2023-10-12 Astrazeneca Ab Combination therapy for treating cancer
WO2024074959A1 (en) 2022-10-02 2024-04-11 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
FR2656609B1 (fr) 1989-12-28 1992-03-27 Synthelabo Derives de 2-aminopyrimidine-4-carboxamide, leur preparation et leur application en therapeutique.
CZ244394A3 (en) 1993-10-08 1995-06-14 Shell Int Research Herbicidal 1,2,4-oxadiazolecarboxylic acids amides, esters or halides
FR2741342B1 (fr) 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
WO2000017163A1 (fr) 1998-09-22 2000-03-30 Yamanouchi Pharmaceutical Co., Ltd. Derives de cyanophenyle
KR20040053210A (ko) 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료
US20050101657A1 (en) 2001-12-28 2005-05-12 Takeda Chemical Industries Ltd. Androgen receptor antagonists
MXPA04005847A (es) * 2001-12-28 2004-09-13 Bayer Pharmaceuticals Corp Compuestos derivados de 4-sulfuro/sulfoxido/sulfonil-1h-pirazolilo, para uso en enfermedades asociadas con el receptor 5-ht2c.
CA2471880A1 (en) * 2001-12-28 2003-07-17 Bayer Pharmaceuticals Corporation 1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
US20040180889A1 (en) 2002-03-01 2004-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
TW200406386A (en) * 2002-06-07 2004-05-01 Novartis Ag Organic compounds
PL374970A1 (en) * 2002-08-02 2005-11-14 Argenta Discovery Limited Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors
DE10322108B4 (de) 2003-05-09 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Antiandrogene Pyrrolidine mit tumorhemmender Wirksamkeit
US7271188B2 (en) 2003-06-12 2007-09-18 Chugai Seikayu Kabushiki Kaisha Imidazolidine derivatives
WO2005030704A1 (en) 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
CA2579886A1 (en) 2004-09-09 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Novel imidazolidine derivative and use thereof
JP2008007405A (ja) * 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
EP1710237A1 (en) * 2005-04-08 2006-10-11 Bayer CropScience S.A. New heterocyclylethylbenzamide derivatives
MX346924B (es) 2005-05-13 2017-04-05 Univ California Compuestos de diarilhidantoina.
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
AR057656A1 (es) * 2005-07-01 2007-12-12 Ligand Pharm Inc Compuestos moduladores de receptores de androgeno y metodods relacionados
GB0518237D0 (en) * 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US8629147B2 (en) * 2005-11-03 2014-01-14 Chembridge Corporation Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
JP5205274B2 (ja) 2006-11-22 2013-06-05 日本農薬株式会社 新規なピラゾール誘導体、有害生物防除剤及びその使用方法
WO2008124000A2 (en) * 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
US7968536B2 (en) * 2007-06-29 2011-06-28 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as RAF kinase inhibitors
WO2009028543A1 (ja) 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited 置換ピラゾール誘導体
EP2220050A2 (en) 2007-10-26 2010-08-25 The Regents Of The University Of California Diarylhydantoin compounds as androgen receptor modulators
US20090270361A1 (en) 2008-03-26 2009-10-29 Takeda Pharmaceutical Company Limited Substituted pyrazole derivatives and use thereof
CA2725481A1 (en) * 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives

Also Published As

Publication number Publication date
CN102596910B (zh) 2015-11-25
SI3056485T1 (en) 2018-08-31
EP3369732B1 (en) 2021-05-26
PL2493858T3 (pl) 2015-01-30
US8975254B2 (en) 2015-03-10
KR101654529B1 (ko) 2016-09-06
KR20160105927A (ko) 2016-09-07
WO2011051540A8 (en) 2012-04-19
PE20121058A1 (es) 2012-08-18
HRP20140919T1 (hr) 2014-11-21
US20120225867A1 (en) 2012-09-06
PT2493858E (pt) 2014-09-03
CO6531494A2 (es) 2012-09-28
US20200299307A1 (en) 2020-09-24
KR20120102057A (ko) 2012-09-17
US20190100536A1 (en) 2019-04-04
EP2493858A1 (en) 2012-09-05
GEP20166472B (en) 2016-05-10
AU2010311299A1 (en) 2012-04-12
DK3369732T3 (da) 2021-07-26
CN105061313A (zh) 2015-11-18
ES2877248T3 (es) 2021-11-16
LT3056485T (lt) 2018-07-25
NL301041I2 (nl) 2020-09-14
PT3369732T (pt) 2021-07-06
RS57592B1 (sr) 2018-11-30
PL3056485T3 (pl) 2018-12-31
IL218586A (en) 2015-10-29
US9657003B2 (en) 2017-05-23
UA109535C2 (uk) 2015-09-10
NZ598747A (en) 2013-06-28
US20170260206A1 (en) 2017-09-14
US10711013B2 (en) 2020-07-14
JP5763083B2 (ja) 2015-08-12
BR112012008823A2 (pt) 2019-02-19
JP2013508447A (ja) 2013-03-07
CY2020010I2 (el) 2020-11-25
NO2020018I1 (no) 2020-06-17
PT3056485T (pt) 2018-07-31
ES2678073T3 (es) 2018-08-08
EA021170B1 (ru) 2015-04-30
PL3369732T3 (pl) 2021-12-06
SI2493858T1 (sl) 2014-10-30
RS53469B (en) 2014-12-31
CN105061313B (zh) 2017-07-18
US20150203479A1 (en) 2015-07-23
EP3885340A1 (en) 2021-09-29
SI3369732T1 (sl) 2021-08-31
CN102596910A (zh) 2012-07-18
AU2010311299A8 (en) 2012-06-14
EP2754656A1 (en) 2014-07-16
BR112012008823B1 (pt) 2021-01-12
IL238044A (en) 2016-07-31
LUC00154I1 (en.) 2020-05-19
AU2010311299B2 (en) 2014-07-17
DK3056485T3 (en) 2018-07-30
MX2012004867A (es) 2012-06-08
KR101670299B1 (ko) 2016-10-28
LT3369732T (lt) 2021-06-25
EA201270597A1 (ru) 2012-10-30
DK2493858T3 (da) 2014-09-08
LTPA2020514I1 (lt) 2020-07-27
CA2777896A1 (en) 2011-05-05
RS62123B1 (sr) 2021-08-31
HUE039390T2 (hu) 2018-12-28
HRP20181229T1 (hr) 2018-10-05
HRP20211180T1 (hr) 2021-10-15
BR112012008823B8 (pt) 2021-05-25
CA2777896C (en) 2017-05-23
WO2011051540A1 (en) 2011-05-05
ES2486263T3 (es) 2014-08-18
CY1124429T1 (el) 2022-07-22
CL2012000772A1 (es) 2012-08-24
AU2010311299C1 (en) 2023-02-02
WO2011051540A9 (en) 2011-06-23
IL218586A0 (en) 2012-05-31
US10118933B2 (en) 2018-11-06
LUC00154I2 (en.) 2021-02-17
US11046713B2 (en) 2021-06-29
MY159924A (en) 2017-02-15
LTC2493858I2 (lt) 2022-03-25
EP3369732A1 (en) 2018-09-05
ZA201202655B (en) 2012-12-27
SMT201400138B (it) 2014-11-10
CY2020010I1 (el) 2020-11-25
EP2493858B1 (en) 2014-07-02
HK1173442A1 (zh) 2013-05-16
HUE055528T2 (hu) 2021-12-28
EP3056485B1 (en) 2018-05-09
EP3056485A1 (en) 2016-08-17

Similar Documents

Publication Publication Date Title
AR078793A1 (es) Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
AR060050A1 (es) Compuestos moduladores del receptor de s1p y uso de los mismos
CO2020006411A2 (es) Inhibidores de endonucleasa cap-dependientes
PE20181304A1 (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2
AR056025A1 (es) Compuestos de imidazol sustituidos como inhibidores de ksp
CR20160548A (es) Nuevos Derivados de Pirazolo Pirimidina y su Uso como Inhibidores de MALT1
AR035548A1 (es) Compuestos organicos
AR067478A1 (es) Compuestos derivados de morfolina pirimidina
AR050966A1 (es) Derivados de bencimidazol utiles como moduladores selectivos de receptores de androgenos (sarms)
AR080688A1 (es) Derivados de 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3.5]nonano como agonistas o antagonistas inversos de grelina
AR088828A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
CO6251243A2 (es) Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
AR072969A1 (es) Derivados de ciclohexilamida, composiciones farmaceuticas y usos como antagonistas del receptor del factor de liberacion de corticotropina (crf - 1)
RU2009105496A (ru) Аминоиндановое производное или его соль
AR070521A1 (es) Derivados de 4h-pirido[4,3-d]-pirimidin-4-ona,inhibidores de quinasas,composiciones farmaceuticas que los contienen,uso de los mismos para el tratamiento de enfermedades con proliferacion celular o autoinmunes y metodo de preparacion de intermediarios de sintesis .
AR074426A1 (es) Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
AR080467A1 (es) Derivados tetrazolicos moduladores selectivos de receptores cb2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor y otras enfermedades
DOP2006000076A (es) Derivados de ciclopentapiridina y tetrahidroquinolina
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
ES2630079T3 (es) Moduladores de la ruta del complemento y usos de los mismos
AR049711A1 (es) Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR080032A1 (es) Compuestos de pirazol como antagonistas de crth2

Legal Events

Date Code Title Description
FG Grant, registration